Results

Total Results: 2,080 records

Showing results for "drug".

1561. Disposition of Comments Report for Recurrent Nephrolithiasis in Adults (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/related_files/kidney-stone-prevention_disposition-comments.pdf
      July 26, 2012 - This is impractical and for all intents and purposes, this drug is not available in the US.

1562. Nonopioid Pharmacologic Treatments for Chronic Pain: Appendix E (xls file)
      effectivehealthcare.ahrq.gov/sites/default/files/nonopioid-chronic-pain-ape_0.xlsx
      August 08, 2017 - myocardial infarction; NA = not applicable; NR = not reported; NSAID = nonsteroidal anti-inflammatory drug … rate ratio; SMD: standardized mean difference; tNSAID = traditional nonsteroidal anti-inflammatory drug

1563. Disposition of Comments_Comparative Effectiveness Review No. 262_Pharmacotherapy for Adults With Alcohol Use Disorder in Outpatient Settings: Systematic Review (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-262-pharmacotherapy-alcohol-disposition-comments.pdf
      November 07, 2023 - effect is apparently due to a wish to avoid an unpleasant experience and not a direct effect of the drug … Since the research subject does not know whether they've received placebo or active drug, both treatment

1564. Disposition of Comments Report for Enzyme-Replacement Therapies for Lysosomal Storage Disease (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/related_files/lysosomal-storage-diseases-therapies_disposition-comments.pdf
      January 01, 2014 - The purpose of a Technical Brief is to provide an overview of the evidence for a technology, drug … It is treated with a FDA approved drug, Cystagon. This is nowhere in your document. 2. … 6 Para 3 In the third paragraph of page 6, we believe that the reference to an “average annual drug … Drug shortages: the author alludes to shortages in Europe and Australia, but shortages were a severe … article only if we used the text phrase “enzyme replacement therapy” OR “ERT”, or the subheading “drug

1565. Newer Medications for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pdf/prostatic-hyperplasia-medications_research-protocol.pdf
      April 21, 2015 - In the early 1990s, the Federal Drug Administration (FDA) approval of medications for BPH shifted LUTS … prostates with either agent are supported by systematic reviews.10, 13 Recently, newer drugs and other drug … Common medications used to treat LUTS associated with BPH Drug class - Mechanism of action Medication … , drug manufacturer, device trade name, keyword] 109. exp Product Surveillance, Postmarketing/ 110 … . exp "Drug-Related Side Effects and Adverse Reactions"/ 111. exp Adverse Drug Reaction Reporting Systems

1566. Impact of Employment Interventions for Persons with Serious Mental Illnesses (SMI) on Non-Employment Patient-Centered Outcomes | Effective Health Care Program
      effectivehealthcare.ahrq.gov/products/mental-illness-employment/abstract
      December 20, 2011 - and somatic chronic care; and (3) patient-reported outcomes, including functional status, alcohol and drug

1567. Topic Suggestion Description | Effective Health Care Program
      effectivehealthcare.ahrq.gov/get-involved/nominated-topics/comparative-effectiveness-for-the-treatment-of-major-depressive-disorder-mdd-key-questions-1-for-the-treatment-of-mdd-what-is-the-comparative-effectiveness-of-ssris-placebo-psychotherapy-exercise-and-alternative-therapies-2-f
      March 11, 2013 - Appropriateness for EHC Program Does your question include a health care drug, intervention, device

1568. Please help find something to ease my mothers pain with restless leg syndrome? It has bothered her for over 30 years and now is almost unbearable at 78 years old. It has really diminished her joy in life. | Effective Health Care (EHC) Program
      effectivehealthcare.ahrq.gov/get-involved/nominated-topics/please-help-find-something-to-ease-my-mothers-pain-with-restless-leg-syndrome-it-has-bothered-her-for-over-30-years-and-now-is-almost-unbearable-at-78-years-old-it-has-really-diminished-her-joy-in-life
      January 06, 2010 - Appropriateness for EHC Program Does your question include a health care drug, intervention, device

1569. What are the best options for fertility treatment, in terms of safety and effectiveness? | Effective Health Care (EHC) Program
      effectivehealthcare.ahrq.gov/get-involved/nominated-topics/what-are-the-best-options-for-fertility-treatment-in-terms-of-safety-and-effectiveness
      January 31, 2013 - None Appropriateness for EHC Program Does your question include a health care drug, intervention

1570. Is there an easier way to test for Celiac disease? | Effective Health Care (EHC) Program
      effectivehealthcare.ahrq.gov/get-involved/nominated-topics/is-there-an-easier-way-to-test-for-celiac-disease
      March 11, 2012 - Appropriateness for EHC Program Does your question include a health care drug, intervention, device

1571. #06 Developmental Delays ADHD, and Autism (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/06_devdelays_autism_potential_high_impact_june_2012.pdf
      January 01, 2012 - similar drugs in the same class are read separately), and then topics in the same class of a device, drug

1572. Evaluation and Treatment of Tinnitus: Comparative Effectiveness | Effective Health Care (EHC) Program
      effectivehealthcare.ahrq.gov/products/tinnitus/research
      August 23, 2013 - Current Page Topic Timeline Feb. 17, 2012 Topic Suggestion Feb. 22, 2012 Research Protocol Aug. 23, 2013 Systematic Review Nov. 27, 2013 Disposition of Comments Report Evaluation and Treatment of Tinnitus: Comparative Effectiveness Systematic Review Archived August 23, 2013 Web Version [NLM Site] Download Main Doc…

1573. Treatment of Dementia Among Community-Dwelling and Institutionalized Medicare Beneficiaries | Effective Health Care (EHC) Program
      effectivehealthcare.ahrq.gov/products/dementia-databases-methods/research
      May 22, 2008 - Preventive Medicine, University of Maryland School of Medicine, Baltimore, MD. 2 Peter Lamy Center on Drug … settings was also found despite the different method of measuring medication use, with institutional drug … This relationship also held in the community, albeit overall rates of drug use were lower (15.5% versus … particularly important to replicate this work given that new drugs (specifically memantine) and other drug … The quality of antipsychotic drug prescribing in nursing homes.

1574. Psoriasis-Chronic Executive (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/related_files/psoriasis-chronic_executive.pdf
      November 01, 2012 - etanercept, and adalimumab), and one anti-IL 12/23 agent (ustekinumab) have approval from the Food and Drug … agents concluded a difference in efficacy, suggesting heterogeneity within the class and indicating drug … and therefore do not make between-class comparisons, rather limit comparisons with the individual drug … systemic biologic agents and systemic nonbiologic agents (between-class comparisons on an individual drug … systemic biologic agents and systemic nonbiologic agents (between-class comparisons on an individual drug

1575. Comparative Effectiveness of Second Generation Antidepressants in the Pharmacologic Treatment of Adult Depression – An Update to a 2007 Report | Effective Health Care (EHC) Program
      effectivehealthcare.ahrq.gov/products/antidepressants-update/research-protocol
      July 13, 2011 - relapse (i.e., continuation phase) or recurrence (i.e., maintenance phase) when a patient continues the drug … medications with new formulations (such as an extended release formulation) are approved by the Food and Drug … Administration (FDA) through an application called a supplemental new drug application (sNDA). … of interest is whether response or remission can be maintained if patients who have responded to one drug … If fewer than three head-to-head trials are available for any drug comparison, we will compute indirect

1576. Evidence Report on the (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pdf/antidepressants-update_research-protocol.pdf
      July 13, 2011 - , continuation phase) or recurrence (i.e., maintenance phase) when a patient 1) continues the drug … medications with new formulations (such as an extended release formulation) are approved by the Food and Drug … Administration (FDA) through an application called a supplemental new drug application (sNDA). … interest is whether response or remission can be maintained if patients who have responded to one drug … If fewer than three head-to-head trials are available for any drug comparison, we will compute indirect

1577. #06 Developmental Delays ADHD, and Autism (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/developmental-delays-horizon-scan-high-impact-1506.pdf
      December 01, 2015 - similar drugs in the same class are read separately), and then topics in the same class of a device, drug … study examining metadoxine for treating adult ADHD; a similar trial is also planned to study this drug

1578. PREGNANCY, INCLUDING PRETERM BIRTH #12 (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pregnancy-horizon-scan-high-impact-1412.pdf
      December 01, 2014 - similar drugs in the same class are read separately), and then topics in the same class of a device, drug … spontaneous preterm birth; interventions intended to target both the pregnant woman and fetus (a drug

1579. Interventions to Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer's-Type Dementia | Effective Health Care (EHC) Program
      effectivehealthcare.ahrq.gov/products/cognitive-decline/research-2017
      March 24, 2017 - Many interventions (e.g., nutraceuticals; one multimodal intervention using lifestyle advice and drug

1580. #14 SUBSTANCE ABUSE (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/substance-abuse-horizon-scan-high-impact-1512.pdf
      December 01, 2015 - Recent marketing data collected by the FDA’s Center for Drug Evaluation and Research indicates that … The drug potentially holds additional promise as an AUD therapy because its safety profile is better … Hazardous drinkers and drug users in HMO primary care: prevalence, medical conditions, and costs. … Mobile medical applications: guidance for industry and Food and Drug Administration staff. … Food and Drug Administration (FDA); 2015 Feb 9. 44 p.